Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan

Therapeutic improvements are needed for patients with acute myeloid leukemia (AML), particularly those who have relapsed or who have treatment‐refractory (R/R) AML or newly diagnosed patients with poor prognostic factors. Alvocidib (DSP‐2033), a potent cyclin‐dependent kinase 9 inhibitor, has previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikezoe, Takayuki, Ando, Kiyoshi, Onozawa, Masahiro, Yamane, Takahisa, Hosono, Naoko, Morita, Yasuyoshi, Kiguchi, Toru, Iwasaki, Hiromi, Miyamoto, Toshihiro, Matsubara, Keisuke, Sugimoto, Saori, Miyazaki, Yasushi, Kizaki, Masahiro, Akashi, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746059/
https://www.ncbi.nlm.nih.gov/pubmed/35689544
http://dx.doi.org/10.1111/cas.15458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746059/
https://www.ncbi.nlm.nih.gov/pubmed/35689544
http://dx.doi.org/10.1111/cas.15458

Ejemplares similares